Cantor Fitzgerald Estimates Gilead Sciences FY2025 Earnings

Key Points

• Analysts at Cantor Fitzgerald have raised their FY2025 earnings per share (EPS) estimate for Gilead Sciences to $8.15, an increase from the previous estimate of $8.05.
• Various financial institutions have adjusted their price targets for Gilead Sciences, with targets ranging from $96.00 to $133.00, reflecting a generally positive sentiment towards the stock.
• Gilead Sciences declared a quarterly dividend of $0.79 per share, highlighting a 2.6% dividend yield for shareholders of record as of September 15th.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Gilead Sciences in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings per share of $8.15 for the year, up from their previous forecast of $8.05. Cantor Fitzgerald currently has a "Overweight" rating and a $125.00 target price on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's revenue was up 1.4% on a year-over-year basis. During the same period last year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS.

Other equities research analysts have also recently issued reports about the company. UBS Group raised their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research note on Tuesday. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Oppenheimer dropped their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Finally, Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a report on Friday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Stock Up 0.7%

Shares of GILD traded up $0.82 during mid-day trading on Thursday, hitting $118.81. The company's stock had a trading volume of 3,560,926 shares, compared to its average volume of 8,311,018. The company's 50-day moving average is $111.98 and its 200-day moving average is $108.64. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences has a 52-week low of $74.34 and a 52-week high of $121.83. The firm has a market capitalization of $147.42 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 0.73 and a beta of 0.33.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director directly owned 8,920 shares of the company's stock, valued at $978,880.80. The trade was a 35.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at approximately $18,977,838.30. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 110,000 shares of company stock valued at $12,349,790. Insiders own 0.27% of the company's stock.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nissay Asset Management Corp Japan ADV raised its position in shares of Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares during the period. Golden State Wealth Management LLC raised its stake in Gilead Sciences by 14.5% during the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 109 shares during the last quarter. Mufg Securities Americas Inc. purchased a new position in Gilead Sciences in the 4th quarter worth about $1,699,000. Capital International Inc. CA raised its position in Gilead Sciences by 23.8% in the fourth quarter. Capital International Inc. CA now owns 312,209 shares of the biopharmaceutical company's stock worth $28,839,000 after acquiring an additional 60,035 shares during the period. Finally, ASR Vermogensbeheer N.V. bought a new stake in Gilead Sciences during the 1st quarter valued at approximately $11,688,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.